guest ::
| Home > Publications database > Alpha-Emitting Radionuclides: Current Status and Future Perspectives. > print |
| Home > Publications database > Alpha-Emitting Radionuclides: Current Status and Future Perspectives. > print |
| 001 | 287258 | ||
| 005 | 20241030150643.0 | ||
| 024 | 7 | _ | |a 10.3390/ph17010076 |2 doi |
| 024 | 7 | _ | |a pmid:38256909 |2 pmid |
| 037 | _ | _ | |a DKFZ-2024-00190 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Miederer, Matthias |b 0 |
| 245 | _ | _ | |a Alpha-Emitting Radionuclides: Current Status and Future Perspectives. |
| 260 | _ | _ | |a Basel |c 2024 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1706019574_7566 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a actinium-225 |2 Other |
| 650 | _ | 7 | |a alpha emitter |2 Other |
| 650 | _ | 7 | |a high let |2 Other |
| 650 | _ | 7 | |a targeted alpha therapy |2 Other |
| 650 | _ | 7 | |a theranostic |2 Other |
| 700 | 1 | _ | |a Benešová-Schäfer, Martina |0 P:(DE-He78)0f034e05cefb010f991ef8b96009d95c |b 1 |u dkfz |
| 700 | 1 | _ | |a Mamat, Constantin |0 0000-0003-1906-3186 |b 2 |
| 700 | 1 | _ | |a Kästner, David |b 3 |
| 700 | 1 | _ | |a Pretze, Marc |0 0000-0002-6432-5694 |b 4 |
| 700 | 1 | _ | |a Michler, Enrico |b 5 |
| 700 | 1 | _ | |a Brogsitter, Claudia |b 6 |
| 700 | 1 | _ | |a Kotzerke, Jörg |b 7 |
| 700 | 1 | _ | |a Kopka, Klaus |0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |b 8 |
| 700 | 1 | _ | |a Scheinberg, David A |b 9 |
| 700 | 1 | _ | |a McDevitt, Michael R |b 10 |
| 773 | _ | _ | |a 10.3390/ph17010076 |g Vol. 17, no. 1, p. 76 - |0 PERI:(DE-600)2193542-7 |n 1 |p 76 |t Pharmaceuticals |v 17 |y 2024 |x 1424-8247 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/287258/files/pharmaceuticals-17-00076.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/287258/files/pharmaceuticals-17-00076.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:287258 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)0f034e05cefb010f991ef8b96009d95c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PHARMACEUTICALS-BASE : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T15:01:23Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T15:01:23Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-04-12T15:01:23Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2023-04-12T15:01:23Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-25 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-25 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-25 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-25 |
| 920 | 1 | _ | |0 I:(DE-He78)E270-20160331 |k E270 |l NWG Molekularbiologie Systemischer Radiotherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)DD01-20160331 |k DD01 |l DKTK Koordinierungsstelle Dresden |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E270-20160331 |
| 980 | _ | _ | |a I:(DE-He78)DD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|